Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07652567
NA

Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population

Sponsor: Qilu Hospital of Shandong University

View on ClinicalTrials.gov

Summary

I. Research Objectives Primary Objectives: To evaluate the effect of low-dose antihypertensive therapy on the incidence of new-onset hypertension and new-onset diabetes in individuals with high-normal blood pressure and cardiovascular risk factors. To assess the impact of low-dose antihypertensive therapy on composite cardiovascular events in individuals with high-normal blood pressure and cardiovascular risk factors. Secondary Objective: To evaluate the effects of low-dose antihypertensive therapy and different drug regimens on intermediate markers or subclinical status of cardiovascular disease risk, including lipid profiles, carotid atherosclerosis, and arterial stiffness (pulse wave velocity). II. Study Population Individuals with high-normal blood pressure and comorbid cardiovascular risk factors who have not been treated with antihypertensive medications. III. Endpoints Primary Endpoints: New-onset hypertension and new-onset diabetes. Composite cardiovascular events (fatal and non-fatal stroke, myocardial infarction, cardiovascular death, and coronary revascularization). Other Endpoints: Hospitalization for transient ischemic attack (TIA), hospitalization for angina pectoris, hospitalization for heart failure, peripheral vascular disease, malignancy, all-cause mortality, and renal failure.

Key Details

Gender

All

Age Range

50 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

690

Start Date

2007-01-01

Completion Date

2026-04-30

Last Updated

2026-06-17

Healthy Volunteers

No

Interventions

DRUG

Telmisartan

Patients will receive Telmisartan 40 mg, administered as one tablet once daily.

DRUG

Indapamide

Patients will receive Indapamide 1.5 mg, administered as one capsule every other day.

OTHER

Placebo

Patients will receive a placebo, administered as half a tablet once daily.

Locations (1)

Qilu Hospital of Shandong University

Jinan, Shandong, China